AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Anzu-cel shows favorable tolerability, strong anti-tumor activity in Phase 1b trial.
ByAinvest
Wednesday, Aug 13, 2025 7:05 am ET1min read
Anzu-cel, a one-time infusion, has shown favorable tolerability and strong anti-tumor activity in a Phase 1b trial for metastatic melanoma. The trial involved 33 heavily pretreated patients, with a 56% complete response rate, 12.1 months median duration of response, and 15.9 months median overall survival. A global, randomized Phase 3 trial, SUPRAME, is ongoing, with interim and final analyses expected in 2026.
Immatics N.V. (NASDAQ: IMTX) has reported favorable results for its PRAME cell therapy, anzu-cel (IMA203), in a Phase 1b trial for metastatic melanoma. The trial, which involved 33 heavily pretreated patients, demonstrated a 56% complete response rate (cORR), a median duration of response (mDOR) of 12.1 months, and a median overall survival (mOS) of 15.9 months [1].The trial, presented at the 2025 ASCO Annual Meeting, further substantiates Immatics' global leadership in precision targeting of PRAME. The data showed favorable tolerability and promising clinical activity, with a median progression-free survival (mPFS) of 6.1 months and a median follow-up time (mFU) of 13.4 months [1].
Immatics is currently conducting a global, randomized, controlled Phase 3 trial, SUPRAME, to evaluate the efficacy, safety, and tolerability of anzu-cel PRAME cell therapy versus investigator's choice in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor. The trial is designed as a well-controlled clinical trial evaluating anzu-cel as a monotherapy in a late-stage cutaneous melanoma patient population [1].
The primary endpoint for seeking full approval will be blinded independent central review (BICR)-assessed (RECIST v1.1) progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), safety, and patient-reported outcomes about quality of life. The interim and final data analyses will occur in 2026, with the Company on track for a planned Biologics License Application (BLA) submission in 1H 2027 and launch of anzu-cel in 2H 2027 [1].
References:
[1] https://www.marketscreener.com/news/immatics-announces-second-quarter-2025-financial-results-and-business-update-ce7c51dbdc89fe27
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet